Metabolic dysfunction associated steatohepatitis
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive inflammatory liver disease that represents the advanced, aggressive form of metabolic dysfunction-associated steatotic liver disease (MASLD).
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive inflammatory liver disease that represents the advanced, aggressive form of metabolic dysfunction-associated steatotic liver disease (MASLD). It is histologically defined by hepatic steatosis (fat accumulation) occurring together with lobular inflammation, hepatocyte ballooning, and variable degrees of fibrosis. MASH marks a pivotal transition in the natural history of fatty liver disease: whereas simple steatosis is largely reversible, the sustained inflammatory and fibrogenic activity of MASH substantially raises the risk of progression to cirrhosis, hepatocellular carcinoma, and liver-related death. The condition was formerly termed non-alcoholic steatohepatitis (NASH); the renaming to MASH is part of a broader reclassification of steatotic liver disease that emphasizes underlying metabolic dysfunction and removes the stigmatizing "non-alcoholic" and "fatty" terminology, while distinguishing it from alcohol-related and combined (MetALD) forms of liver injury.
MASH is tightly linked to the metabolic syndrome, and its development and progression are driven by obesity, type 2 diabetes, and insulin resistance, with lipotoxicity, oxidative stress, immune dysregulation, and activation of hepatic stellate cells contributing to inflammation and scarring. Its clinical burden extends beyond the liver: MASH is associated with substantial healthcare costs and with extra-hepatic complications, including cardiovascular disease and heart failure, and it commonly co-occurs with impaired kidney function as reflected in reduced glomerular filtration rate (eGFR). Because liver biopsy remains the diagnostic reference standard but is invasive, much current effort focuses on non-invasive risk stratification—using routine laboratory markers, imaging-derived measures such as liver MRI corrected T1 and proton density fat fraction, CT-based composite biomarkers, and machine-learning models—to identify patients with clinically significant fibrosis. Patients with stage F2–F3 (fibrotic) MASH constitute the principal target population for the emerging pharmacotherapies now entering clinical use.
Where the papers sit
18 papers from the last 6 months study metabolic dysfunction associated steatohepatitis directly · updated from PubMed 12 Oct 2026
Study type 0 clinical trials · 1 observational · 2 human data · 15 unclassified
Themes 4 themes · 1 paradigm shift · 1 new direction
-
MASLD Care and Classification
MASLD care is moving toward standardized terminology, evidence-based guidance, and precision-constrained use of noninvasive biomarkers. Reclassification efforts are being aligned with elastography, biopsy, cirrhosis assessment, and pharmacological therapy. The disease is increasingly managed within cardiovascular-kidney-metabolic care rather than as an isolated liver disorder. Economic burden, prevention, and early-life factors broaden the clinical agenda beyond treatment alone.
7 papers · 38.9%
-
Noninvasive MASH Diagnosis
MRI, CT, elastography, metabolomics, and clinical panels are moving assessment away from routine liver biopsy. cT1, magnetic resonance elastography, and hepatic fat fraction are being refined to stage disease and predict mortality risk. Pediatric and obesity-focused studies broaden the settings in which noninvasive tools must perform. Mechanistic work on the PPARα/CCL2 axis remains secondary to the shared diagnostic emphasis.
5 papers · 27.8%
-
Therapy and Fibrosis Outcomes
Resmetirom is being judged against placebo by fibrosis-stage improvement, while semaglutide represents parallel metabolic treatment. Placebo-arm data are clarifying the incidence of cirrhosis in fibrotic disease. Screening people with type 2 diabetes is being assessed for earlier detection and economic value. The shared goal is to connect treatment response and fibrosis stage with clinically meaningful progression.
3 papers · 16.7%
-
Macrophage Inflammation in MASH
Macrophage states are being linked to lipid stress and inflammatory injury in MASH. Lipid-associated and monocyte-derived macrophages recur as distinct contributors whose effects depend on tissue context. Celastrol nanoassemblies and the myeloperoxidase inhibitor mitiperstat extend interest in targeting inflammatory pathways. The main open question is which macrophage programs are harmful, protective, or therapeutically tractable.
3 papers · 16.7%
MASH-associated metabolic and immune changes can be compensatory responses rather than intrinsically pathogenic lesions
The lipidated-amino-acid/PM20D1 study in human and mouse MASH models and the review of liver macrophages in MASH challenge the assumption that disease-associated metabolic loss and macrophage accumulation are uniformly harmful. The PM20D1 study found that MASH depletes the lipidated amino acid C18:1-Leu, that hepatocyte-specific loss of its biosynthetic enzyme worsens disease, and that restoring PM20D1 or administering C18:1-Leu improves established MASH-fibrosis; the macrophage review likewise identifies infiltrating macrophages and lipid-associated macrophages as initially adaptive, promoting lipotoxicity clearance and resolution before chronic exposure converts them to inflammatory and fibrogenic states 42784330Sep 42743990Sep. The resulting change is therapeutic and mechanistic: some MASH-associated responses should be restored or supported, not simply suppressed, while their harmful conversion must be prevented.
MASH is framed as a component of a cardiovascular-renal-hepatic-metabolic syndrome
The review on integrating the liver into the cardiovascular-kidney-metabolic syndrome 42683763Sep treats MASH not only as a progressive liver disease with metabolic comorbidities, but as part of an expanded cardiovascular-renal-hepatic-metabolic framework. Whereas the other papers use MASH primarily as a hepatic disease target, prognostic outcome, screening problem, or treatment indication, this review reports that coexistent MASLD and chronic kidney disease confer additive, stage-dependent mortality risk and proposes integrating the liver into the CKM construct. The resulting change is a systems-level role for MASH in a multisystem syndrome, with hepatic fibrosis positioned as a determinant of risk across that broader framework.
Papers
The 18 papers from the last 6 months that study metabolic dysfunction associated steatohepatitis directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
MASLD Care and Classification (7)
- Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications. Current opinion in nephrology and hypertension · 2 Sept 2026 PMID 42683763
- Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany. Journal of comparative effectiveness research · 22 Jul 2026 PMID 42483986
- A precision-constrained framework for evaluating noninvasive biomarkers in MASLD and beyond. Nature communications · 20 Jul 2026 PMID 42477328
- Asia-Pacific perspectives on the steatotic liver disease (SLD) reclassification: balancing terminology, diagnostic criteria, and implementation. Annals of hepatology · 18 Jun 2026 PMID 42315088
- Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026. Journal of gastroenterology · 12 May 2026 PMID 42120590
- Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026. Hepatology research : the official journal of the Japan Society of Hepatology · 12 May 2026 PMID 42118685
- Breastfeeding in infancy confers sex-specific, long-term protection against metabolic dysfunction-associated steatohepatitis and adverse liver outcomes. Biology of sex differences · 12 May 2026 PMID 42116208
Noninvasive MASH Diagnosis (5)
- Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models. The Journal of clinical investigation · 24 Sept 2026 PMID 42784330
- Clinical and Metabolomic Panel for Noninvasive Screening of Biopsy-Confirmed MASH in Children and Adolescents. JHEP reports : innovation in hepatology · 30 Aug 2026 PMID 42669329
- Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography. Hepatology communications · 11 Aug 2026 PMID 42579768
- Refined liver MRI-derived cT1 thresholds capturing hepatic fat fraction enhance mortality risk prediction. JHEP reports : innovation in hepatology · 17 Jun 2026 PMID 42309239
- Liver CT-based composite biomarkers can identify MASH and steatosis grade in people with obesity prior to bariatric surgery: a retrospective study. BMC gastroenterology · 14 May 2026 PMID 42135651
Therapy and Fibrosis Outcomes (3)
- Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis. JHEP reports : innovation in hepatology · 7 Sept 2026 PMID 42705608
- Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset. Alimentary pharmacology & therapeutics · 29 Jul 2026 PMID 42527732
- Incidence of Cirrhosis in Fibrotic Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Placebo Arms from Randomized Clinical Trials. Digestive diseases and sciences · 18 Jun 2026 PMID 42315723
Macrophage Inflammation in MASH (3)
- Context-Dependent Roles of Liver Macrophages in MASH. Seminars in liver disease · 15 Sept 2026 PMID 42743990
- Engineering oral celastrol-polysaccharide supramolecular nanoassemblies across intestinal barriers for the intervention of nonalcoholic steatohepatitis. Materials today. Bio · 13 Jul 2026 PMID 42440432
- Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat. Pharmacology research & perspectives · 8 May 2026 PMID 42101107
By study type
Observational studies and case reports (1)
- Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography. Hepatology communications · 11 Aug 2026 PMID 42579768
Human data, design not indexed (2)
- Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026. Journal of gastroenterology · 12 May 2026 PMID 42120590
- Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat. Pharmacology research & perspectives · 8 May 2026 PMID 42101107
Unclassified: not yet indexed with MeSH (15)
- Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models. The Journal of clinical investigation · 24 Sept 2026 PMID 42784330
- Context-Dependent Roles of Liver Macrophages in MASH. Seminars in liver disease · 15 Sept 2026 PMID 42743990
- Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis. JHEP reports : innovation in hepatology · 7 Sept 2026 PMID 42705608
- Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications. Current opinion in nephrology and hypertension · 2 Sept 2026 PMID 42683763
- Clinical and Metabolomic Panel for Noninvasive Screening of Biopsy-Confirmed MASH in Children and Adolescents. JHEP reports : innovation in hepatology · 30 Aug 2026 PMID 42669329
- Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset. Alimentary pharmacology & therapeutics · 29 Jul 2026 PMID 42527732
- Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany. Journal of comparative effectiveness research · 22 Jul 2026 PMID 42483986
- A precision-constrained framework for evaluating noninvasive biomarkers in MASLD and beyond. Nature communications · 20 Jul 2026 PMID 42477328
- Engineering oral celastrol-polysaccharide supramolecular nanoassemblies across intestinal barriers for the intervention of nonalcoholic steatohepatitis. Materials today. Bio · 13 Jul 2026 PMID 42440432
- Incidence of Cirrhosis in Fibrotic Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Placebo Arms from Randomized Clinical Trials. Digestive diseases and sciences · 18 Jun 2026 PMID 42315723
- Asia-Pacific perspectives on the steatotic liver disease (SLD) reclassification: balancing terminology, diagnostic criteria, and implementation. Annals of hepatology · 18 Jun 2026 PMID 42315088
- Refined liver MRI-derived cT1 thresholds capturing hepatic fat fraction enhance mortality risk prediction. JHEP reports : innovation in hepatology · 17 Jun 2026 PMID 42309239
- Liver CT-based composite biomarkers can identify MASH and steatosis grade in people with obesity prior to bariatric surgery: a retrospective study. BMC gastroenterology · 14 May 2026 PMID 42135651
- Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026. Hepatology research : the official journal of the Japan Society of Hepatology · 12 May 2026 PMID 42118685
- Breastfeeding in infancy confers sex-specific, long-term protection against metabolic dysfunction-associated steatohepatitis and adverse liver outcomes. Biology of sex differences · 12 May 2026 PMID 42116208
Written from 18 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-26 by GPT. Reviewed by a human editor on 2026-07-24. Drafted by language models from published abstracts; not medical advice.